![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
ASH 2024
1. Updates from ASH-a-Palooza and Mentoring in Hematology/Oncology | Tax Kourelis, MD | #ASH24 Video
1. Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24 Video
1. IMWG Update: Long-Term Follow-Up, Teclistamab in Relapsed/Refractory #Myeloma | Carlyn Tan, MD | #ASH24 Video
1. Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics | Nadine Abdallah, MD| #ASH24 Video
1. Early Relapse Score in Multiple Myeloma | Meral Beksac, MD | #ASH24 Video
2. Building a Myeloma-Specific Score to Predict CAR-T Therapy Toxicities | Utkarsh Goel MD | #ASH24 Video
3. Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma | Andrew Portugese | #ASH24 Video
4. Update on BMS-986393, a GPRC5D #Myeloma CAR-T | Susan Bal, MD | #ASH24 Video
5. Circulating Tumor Cell As a Biomarker for Outcomes in Myeloma | Luca Bertamini, MD | #ASH24 Video
6. Myeloma Treatment: Teclistamab Outcomes in Academic vs. Community Settings | Adeel Khan, MD | #ASH24 Video
7. Myeloma 11 Trial: Carfilzomib Quadruplet Enhances Overall Survival | Charlotte Pawlyn, MD | #ASH24 Video
8. Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24 Video
9. ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24 Video
10. ASH 2024 Wrap-Up: What's next in #Myeloma Treatment | Claudio Cerchione, MD | #ASH24 Video
11. Outcomes of Teclistamab in RRMM Patients Who Had Prior BCMA-Directed Therapy | Danai Dima | #ASH24 Video
12. Dara-RVd lite for High Risk Smoldering Myeloma | Omar Nadeem, MD | #ASH24 Video
13. Treating High-Risk Smoldering Myeloma using CAR-T - CAR-PRISM Study | Omar Nadeem, MD | #ASH24 Video
14. Loss of CD38 and Resistance Patterns in Myeloma | Benjamin Diamond, MD | #ASH24 Video
15. Promising Early Data for Improving Talquetamab Effectiveness for MM | Tarek Mouhieddine, MD | #ASH24 Video
16. Real World Experience of Talquetamab in R/R Myeloma Patients | Ariel Grajales Cruz, MD | #ASH24 Video
17. Does enhanced genetic testing impact myeloma patients? | Santiago Thibaud, MD | #ASH24 Video
18. Management and Outcomes of MGRS (Monoclonal Gammopathy of Renal Significance) | Danai Dima | #ASH24 Video
19. High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma | Urvi Shah, MD | #ASH24 Video
20. Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24 Video
21. Understanding the Role of Magnesium for Myeloma Patients | Urvi Shah, MD | #ASH24 Video
22. Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24 Video
23. Daratumumab + Lenalidomide vs Lenalidomide Maintenance in Myeloma | Laahn Foster, MD | #ASH24 Video
24. Plasmacytomas are More Genomically Complex than Myeloma in the Bone Marrow | Urvi Shah, MD | #ASH24 Video
25. Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee | #ASH24 Video
26. 24-hour Urine Testing Does Not Add Value to Myeloma Response Assessments | Rahul Banerjee | #ASH24 Video
27. Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024 Video
28. Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024 Video
29. Social Determinants of Health Impact Myeloma FISH Testing | Amy Pierre, MSN, RN, ANP-BC | #ASH24 Video
30. Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24 Video
31. Understanding the ASH Research Collaborative- COSMIC Study | Saad Usmani, MD | #ASH24 Video
32. Teclistamab Step-Up Dosing to Prevent CRS in Relapse/Refractory MM | Jeffrey Matous, MD | #ASH24 Video
33. Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi , PhD & Erin Meermeier, PhD | #ASH24 Video
34. Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24 Video
35. Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24 Video
36. Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24 Video
37. Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24 Video
38. Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24 Video
39. Study Shows Promise for Non-Invasive MRD Testing for Myeloma Patients | Dory Abelman PhD(c) | #ASH24 Video
40. Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24 Video
41. Myeloma Updates: High-Risk Smoldering, MRD, IVIG, and Maintenance | Natalie Callander, MD | #ASH24 Video
42. Myeloma Patient Experiences with Talquetamab | Jay Hydren, PhD, CSCS | #ASH24 Video
43. Side Effect Severity & Decision-Making Autonomy in Myeloma | Jay Hydren, PhD, CSCS | #ASH24 Video
44. Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24 Video
45. Improving Myeloma Monitoring: Eliminating Sequential Tests | Jean Sebastien Claveau, MD | #ASH24 Video
46. ICAHT After CAR-T for Myeloma: a Stem Cell Boost Solution | Carolina Schinke, MD | #ASH24 Video
47. Talquetamab Efficacy & Toxicity in African American Myeloma Patients | Carolina Schinke, MD | #ASH24 Video
48. Etentamig with Dexamethasone: Promising 2nd Line Therapy for RRMM | Muhamed Baljevic, MD | #ASH24 Video
49. Combination of Selinexor, Pomalidomide, & Dexamethasone for RRMM | Muhamed Baljevic, MD | #ASH24 Video
50. CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD | #ASH24 Video
51. MRD Status in Myeloma: Insights on Changes During Maintenance | Ross Firestone, MD, PhD | #ASH24 Video
52. KarMMa Study: Immune Profiling in CAR-T Therapy for Myeloma | Bruno Paiva, PhD | #ASH24 Video
53. Impact of Triplet Therapy for Fit Elderly Myeloma Patients | Maria Victoria Mateos, MD, PhD | #ASH24 Video
54. Looking Back: Real-World Data on CAR-T and Bispecifics for RRMM | Natalia Neparidze, MD | #ASH24 Video
55. IVIG and Preventing Infections in Myeloma Patients on Teclistamab | Heloise Cheruvalath | #ASH24 Video
56. CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24 Video
57. Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman, MD | #ASH24 Video
58. Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24 Video
59. Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman | #ASH24 Video
60. The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24 Video
61. Belentamab Plus Cyclophosphamide & Dexamethasone in RRMM (ProMMise Study) | Rakesh Popat | #ASH24 Video
62. MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat | #ASH24 Video
63. Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24 Video
64. Cytomegalovirus Reactivation in Myeloma Patients on Teclistamab | Francesca Cottini, MD | #ASH24 Video
65. Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24 Video
66. Real-World Outcomes of Monoclonal Gammopathy of Renal Significance | Francesca Cottini, MD | #ASH24 Video
67. Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24 Video
68. Belantamab Mafodotin with Carfilzomib, Lenalidomide, & Dex for Early Relapse Myeloma | Shebli Atrash, MD | #ASH24 Video
69. Optimizing Modakafusp Alfa for Relapsed/Refractory Multiple Myeloma | Shebli Atrash, MD | #ASH24 Video
70. Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24 Video
71. KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, PhD | #ASH24 Video
72. New Insights for Amyloidosis in Myeloma | Suzanne Lentzsch, MD | #ASH24 Video
73. Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma | Luca Paruzzo, MD | #ASH24 Video
74. Demonstrating Better Protection with 3 Flu Shots in Myeloma | Craig Hofmeister, MD, MPH | #ASH24 Video
75. Comparing Outcomes in Younger Multiple Myeloma Patients | Marc Braunstein, MD, PhD | #ASH24 Video
76. Ethnic Disparities in Myeloma Outcomes | Muzaffar Qazilbash, MD | #ASH24 Video
77. DREAMM-7 Trial Update: Belantamab's Impact on Myeloma Treatment | Robert Rifkin, MD | #ASH24 Video
78. MM-6 Trial: In-class transition to Ixazomib in Newly Diagnosed Myeloma | Robert Rifkin, MD | #ASH24 Video
79. Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24 Video
80. Teclistamab Optec Trial: Prophylactic Toci and Dex during Step-up Doisng | Robert Rifkin, MD | #ASH24 Video
81. Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24 Video
82. Using whole genome sequencing to differentiate between low-risk and high-risk smoldering myeloma | Mehmet Samur, PhD | #ASH24 Video
83. Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24 Video
84. Bone Marrow Spatial Signatures Predict Outcomes in R/R Myeloma Patients | Yoshinobu Konishi, MD, PhD | #ASH24 Video
84. Outcomes in Monoclonal Gammopathy of Renal Significance with Novel Agents | Hira Shaikh and Mehndi Dandwani | #ASH24 Video
85. Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD | #ASH24 Video
85. Talquetamab in BCMA-Exposed Relapsed/Refractory Multiple Myeloma | Hira Shaikh, MD | #ASH24 Video
86. MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24 Video
87. Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24 Video
88. Myeloma Patient Preferences: HealthTree Decision-Making Survey | Manni Mohyuddin, MD | #ASH24 Video
89. Can Mass-Fix Replace Bone Marrow Biopsy? | Angela Dispenzieri, MD | #ASH24 Video
90. New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24 Video
91. Lovesick: Examining Couples Health During Myeloma Transplant | Ashley Rosko, MD | #ASH24 Video
92. MRD2STOP: Can multiple myeloma patients stop treatment? | Ben Derman, MD | #ASH24 Video
Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman | #ASH24
Last year
Lesson Description
Ciara Freeman, MD presents research on identifying genetic features that predict patient responses to CAR-T and bispecific therapies targeting the BCMA antigen in myeloma. By analyzing bone marrow samples through whole genome sequencing, the team aims to personalize treatment plans, focusing on genetic profiles and disease markers to optimize outcomes for patients with different myeloma characteristics.